Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
The TRIPs Agreement and Pharmaceuticals. Report of an ASEAN Workshop on the TRIPs Agreement and its Impact on Pharmaceuticals. Jakarta, 2-4 May 2000
(2000; 91 pages) View the PDF document
Table of Contents
View the documentACKNOWLEDGEMENTS
View the documentLIST OF ABBREVIATIONS AND ACRONYMS
View the documentEXECUTIVE SUMMARY
View the documentI. INTRODUCTION
Open this folder and view contentsII. GENERAL ISSUES
Open this folder and view contentsIII. TECHNICAL ISSUES
Open this folder and view contentsIV. SPECIAL ISSUES
View the documentV. ISSUES DISCUSSED IN WORKING GROUPS
View the documentVI. RECOMMENDATIONS
Open this folder and view contentsANNEXES
 

LIST OF ABBREVIATIONS AND ACRONYMS

Agreement

the TRIPs Agreement (see: TRIPs)

AIDS

Acquired Immune Deficiency Syndrome

ASEAN

Association of South-East Asian Nations

AZT

3’-azido-3’-deoxythymidine (also known as zidovudine)

BMS

Bristol-Myers Squibb

CBD

Convention on Biological Diversity

CL

compulsory license

ddI

didanosine

DNA

deoxyribonucleic acid

EPO

European Patent Office

EU

European Union

FDA

Food and Drug Administration

FDI

Foreign Direct Investment

GATT

General Agreement on Tariffs and Trade

GI

Genetics Institute

GM

Genetically modified

GMOs

Genetically modified organisms

GP Farmasi

Gabungan Pengusaha Farmasi (Indonesian Pharmaceutical Industry Association)

HIV

human immune deficiency virus

IFPMA

International Federation of Pharmaceutical Manufacturers

ICH

International Conference on Harmonization

IMF

International Monetary Fund

INN

international non-proprietary name

IP

intellectual property

IPR

intellectual property rights

LDC

least developed countries

MFN

most-favoured-nation

MNC

multi-national companies

MOH

Ministry of Health

NAFTA

North American Free Trade Agreement

NCE

new chemical entity

NGO(s)

non-governmental organization(s)

NIH

National Institute of Health

PTO

Patent and Trademark Office

R&D

research and development

SK-F

Smith Kline and French

SMP

safety monitoring program

TB

tuberculosis

TK

traditional knowledge

TRIPs

(Agreement on) Trade-Related Aspects of Intellectual Property rights

UK

United Kingdom

UNDP

United Nations Development Program

UNIDO

United Nations Industrial Development Organization

US

United States (of America)

USPTO

US Patent and Trademark Office

USTR

US Trade Representative

WB

World Bank

WIPO

World Intellectual Property Organization

WHO

World Health Organization

WTO

World Trade Organization

This report has been compiled by Karin Timmermans and Togi Hutadjulu.

Sections I, II, III and IV are based on the presentations and/or papers of the following resource persons:

Dr. Carlos M. Correa
University of Buenos Aires, Argentina

Paragraph I, 2.1, 2.3, 2.5, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.9, 3.11 and 3.12

Dr. Cita Priapantja
IPR Society, Indonesia

Paragraph 3.9

Dr. German Velasquez
World Health Organization

Paragraph 2.2

Dr. Harvey E. Bale
International Federation of Pharmaceutical Manufacturers

Paragraph 2.4.1

Mr. James Love
Consumer Project on Technology, US

Paragraph 3.3, 3.4, 3.5, 3.9 and 3.10

Drs. Kai Arief Iman Selomulya
Indonesian Pharmaceutical Association

Paragraph 2.4.2

Dr. Kumariah Balasubramaniam
Consumers International, Malaysia

Paragraph 2.4.3

Mr. Matthew Kennedy
World Trade Organization

Paragraph 2.1, 3.1 and 3.5

Dr. Mohan D. Nair
Pharmaceutical Industry Consultant, India

Paragraph 4.2 and 4.3

Mr. Shakeel Bhatti
World Intellectual Property Organization

Paragraph 2.1, 2.5 and 4.1

Ms. Yuwadee Patanawong
Food and Drug Administration, Thailand

Paragraph 3.8

Dr. Wattana S. Janjaroen
Chulalongkorn University, Thailand

Paragraph 2.5

Sections V and VI are based on the input from participants and delegates.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014